Q2 2025 · 13F-HR
Pivotal bioVenture Partners Investment Advisor LLCholdings as filed
Filed 2025-08-13 · accession 0001012975-25-000438
$161.3M
Reported value
12
Positions
2025-06-30
Period end
The Brief · Pivotal bioVenture Partners Investment Advisor LLC · Q2 2025
AI · grounded in 13F
Pivotal bioVenture Partners Investment Advisor LLC established a new position in OCS valued at $44.66M. The fund also initiated new stakes in PCVX for $42.43M and ARQT for $29.73M. Additional new positions include INOZYME PHARMA INC at $17.98M and ZBIO at $7.55M. Total assets under management stand at $161.34M across 12 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| H5870P102 | OCS | OCULIS HOLDING AG | $44.7M | 27.7% | 2,300,774 | Common | SHARED |
| 92243G108 | PCVX | VAXCYTE INC | $42.4M | 26.3% | 1,305,125 | Common | SHARED |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $29.7M | 18.4% | 2,120,508 | Common | SHARED |
| 45790W108 | — | INOZYME PHARMA INC | $18.0M | 11.1% | 4,494,851 | Common | SHARED |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $7.5M | 4.68% | 779,045 | Common | SHARED |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $6.3M | 3.89% | 1,146,110 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $4.5M | 2.76% | 560,595 | Common | SHARED |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $3.0M | 1.87% | 595,518 | Common | SHARED |
| 09077V100 | BIOA | BIOAGE LABS INC | $2.7M | 1.67% | 653,374 | Common | SHARED |
| 449778109 | IOBTQ | IO BIOTECH INC | $1.2M | 0.74% | 864,197 | Common | SHARED |
| 75120L100 | RLYB | RALLYBIO CORP | $812,770 | 0.50% | 2,404,644 | Common | SHARED |
| 097702203 | BOLT | BOLT BIOTHERAPEUTICS INC | $545,686 | 0.34% | 94,573 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.